Figure 1.

Pathophysiology of CF Disease. Process by which mutations in CFTR ultimately lead to reduced lung functional capacity. Therapeutic strategies currently target all phases of this process: Gene therapy and gene editing target the gene defect; RNA and protein therapies and modulating alternative channels aim to improve ion transport; early therapeutic paradigms targeted the downstream consequences of this process with airway clearance techniques, mucolytics, antibiotics and lung transplantation.